Pharmapace, Inc.
Home
About Us
  • Who Are We?
  • Leadership
  • Core Business
  • Therapeutic Experience
  • How We Manage Your Data
  • Drugs We Helped Approved
  • Events & Impact
  • Publications
Services
  • Biostatistics
  • Data Management
  • Statistical Programming
  • CDISC (SDTM/ADaM)
  • Regulatory Submissions
  • Clinical Data Integration
  • ClinicalTrials.gov Submit
  • Medical Writing
  • FSP
  • BIMO
  • PK/PD Analysis
  • Project Management
Contact Us
Pharmapace, Inc.
Home
About Us
  • Who Are We?
  • Leadership
  • Core Business
  • Therapeutic Experience
  • How We Manage Your Data
  • Drugs We Helped Approved
  • Events & Impact
  • Publications
Services
  • Biostatistics
  • Data Management
  • Statistical Programming
  • CDISC (SDTM/ADaM)
  • Regulatory Submissions
  • Clinical Data Integration
  • ClinicalTrials.gov Submit
  • Medical Writing
  • FSP
  • BIMO
  • PK/PD Analysis
  • Project Management
Contact Us
More
  • Home
  • About Us
    • Who Are We?
    • Leadership
    • Core Business
    • Therapeutic Experience
    • How We Manage Your Data
    • Drugs We Helped Approved
    • Events & Impact
    • Publications
  • Services
    • Biostatistics
    • Data Management
    • Statistical Programming
    • CDISC (SDTM/ADaM)
    • Regulatory Submissions
    • Clinical Data Integration
    • ClinicalTrials.gov Submit
    • Medical Writing
    • FSP
    • BIMO
    • PK/PD Analysis
    • Project Management
  • Contact Us
  • Home
  • About Us
    • Who Are We?
    • Leadership
    • Core Business
    • Therapeutic Experience
    • How We Manage Your Data
    • Drugs We Helped Approved
    • Events & Impact
    • Publications
  • Services
    • Biostatistics
    • Data Management
    • Statistical Programming
    • CDISC (SDTM/ADaM)
    • Regulatory Submissions
    • Clinical Data Integration
    • ClinicalTrials.gov Submit
    • Medical Writing
    • FSP
    • BIMO
    • PK/PD Analysis
    • Project Management
  • Contact Us

Publications

LZ Shen, J O’QUIGLEY – Biometrika, 1996 – academic.oup.com

Consistency of continual reassessment method under model misspecification

MS Fineman, T Bicsak, L Shen, K Taylor, E Gaines… – Diabetes, 2002 – insights.ovid.com

AC2993 (synthetic exendin-4) added to existing metformin (Met) and/or sulfonylurea (SFU) treatment improved glycemic control in patients with type 2 …

T Poon, P Nelson, L Shen, M Mihm… – Diabetes …, 2005 – online.liebertpub.com

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

MS Fineman, LZ Shen, K Taylor… – Diabetes/metabolism …, 2004 – Wiley Online Library

Effectiveness of progressive dose‐escalation of exenatide (exendin‐4) in reducing dose‐limiting side effects in subjects with type 2 diabetes

F Whitehouse, DF Kruger, M Fineman, L Shen… – Diabetes …, 2002 – Am Diabetes Assoc

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

PA Hollander, P Levy, MS Fineman, DG Maggs… – Diabetes …, 2003 – Am Diabetes Assoc

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes

P Hollander, R Ratner, M Fineman… – Diabetes, Obesity …, 2003 – Wiley Online Library

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

LZ Shen – Statistics & probability letters, 1993 – Elsevier

On Chiang’s explicit solutions for the Kolmogorov differential equations

L Zaiqian Shen – Communications in statistics-theory and methods, 1994 – Taylor & Francis

On optimal B-robust influence functions in multidimensional parametric models

LZ Shen – The Annals of Statistics, 1995 – JSTOR

On optimal B-robust influence functions in semiparametric models

LZ Shen – Statistica Sinica, 1995 – JSTOR

Robust Estimation for Semiparametric Exponential Mixture Models

LZ Shen – Statistics & Risk Modeling, 1994 – degruyter.com

Optimal robust estimates for semiparametric symmetric location models

J O’Quigley, LZ Shen – Biometrics, 1996 – JSTOR

Continual reassessment method: a likelihood approach

LZ Shen, HR Al-Khalidi – Communications in statistics-theory and …, 1997 – Taylor & Francis

Application of boundary calculation methodologies to group sequential testing in general parametric models

LZ Shen, E Pulkstenis, M Hoseyni – Statistics in medicine, 1999 – Wiley Online Library

Estimation of mean quality adjusted survival time

J O’Quigley, LZ Shen, A Gamst – … of Biopharmaceutical Statistics, 1999 – Taylor & Francis

Two-sample continual reassessment method

LZ Shen, J O’Quigley – Computational statistics & data analysis, 2000 – Elsevier

Using a one-parameter model to sequentially estimate the root of a regression function

LZ Shen, MS Fineman, A Baron – Drug information journal, 2006 – journals.sagepub.com

Design and analysis of dose escalation studies to mitigate dose-limiting adverse effects

LZ Shen, J Zhou – Therapeutic Innovation & Regulatory …, 2006 – search.proquest.com

A practical and efficient approach to database quality audit in clinical trials

LZ Shen, T Coffey, W Deng – Journal of biopharmaceutical …, 2008 – Taylor & Francis

A Bayesian approach to utilizing prior data in new drug development

M Zhou, LZ Shen – Therapeutic Innovation & Regulatory …, 2014 – journals.sagepub.com

A Novel Design for Decision Rules Based on Statistical Testing Strategies of Binary Endpoints in a Definitive Go/No-Go Single-Treatment Clinical Study

LZ Shen – Journal of Emergency Medicine, 1993 – jem-journal.com

Statistical review

DM Burns, L Lee, LZ Shen, E Gilpin, HD Tolley… – pdfs.semanticscholar.org

Cigarette Smoking Behavior in the United States (PDF)

A Buch, L Shen, S Kelly, R Sahota, C Brezovic, C Bixler… – 1998 – journals.lww.com

Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.

AB Buch, LZ Shen, SC Kelly, DA Russell, RS Sahota… – …, 1999 – Taylor & Francis

Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems

D Maggs, L Shen, S Strobel, D Brown, O Kolterman… – Metabolism, 2003 – Elsevier

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis

RE Ratner, R Dickey, M Fineman, DG Maggs… – Diabetic …, 2004 – Wiley Online Library

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year …

OG Kolterman, DD Kim, L Shen… – American Journal of …, 2005 – search.ebscohost.com

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

T Poon, P Nelson, L Shen, M Mihm… – Diabetes …, 2005 – online.liebertpub.com

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

R Ratner, F Whitehouse, MS Fineman… – Experimental and …, 2005 – thieme-connect.com

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes …

C Weyer, MS Fineman, S Strobel… – American journal of …, 2005 – search.ebscohost.com

Properties of pramlintide and insulin upon mixing.

Pharmapce, Inc. 

10509 Vista Sorrento Pkwy, Ste 303, San Diego, CA 92121

🇺🇸 

Proud U.S.-Based Company. 

Proud U.S.-Based Team. 

Proud U.S.-Based Servers.  

  • Home
  • Leadership
  • Core Business
  • Contact Us

Copyright © 2025 Pharmapace - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept